SNRPA1 (small nuclear ribonucleoprotein polypeptide A') is a spliceosomal component essential for pre-mRNA splicing, where it functions as part of the U2 snRNP complex and contributes to binding of U2 snRNA stem loop IV 123. Beyond canonical splicing, SNRPA1 plays critical roles in pluripotency: it is significantly upregulated during reprogramming to induced pluripotent stem cells and is required for pluripotency maintenance through regulation of spliceosome assembly 4. SNRPA1 is dysregulated in multiple malignancies. In colorectal cancer, SNRPA1 overexpression promotes proliferation and tumor formation by regulating oncogenic pathways involving PIK3R1, VEGFC, MKI67, and CDK1 5, while it also facilitates p53 inactivation through interaction with lncRNA RMRP, promoting resistance to PARP inhibitors 6. High SNRPA1 expression correlates with poor prognosis in lung adenocarcinoma and prostate cancer, where it enhances cell proliferation, migration, and epithelial-mesenchymal transition 78. Additionally, SNRPA1 was identified as a predictive biomarker for obstructive ventilatory dysfunction with nontuberculous mycobacterial infection 9. In spinal muscular atrophy, SNRPA1 upregulation in spinal cord tissue correlates with other dysregulated genes 10. These findings establish SNRPA1 as a therapeutic target in cancer and potential biomarker in several diseases.